Loading...
XTSECPH
Market cap262mUSD
Dec 24, Last price  
14.74CAD
1D
0.55%
1Q
3.44%
Jan 2017
200.82%
Name

Cipher Pharmaceuticals Inc

Chart & Performance

D1W1MN
XTSE:CPH chart
P/E
12.88
P/S
12.41
EPS
0.80
Div Yield, %
0.00%
Shrs. gr., 5y
-1.20%
Rev. gr., 5y
-1.44%
Revenues
21m
+2.36%
25,417,172646,633778,997543,2691,267,8713,036,0045,384,1383,495,5928,501,95525,367,9198,258,99534,409,00040,740,00040,320,00022,749,00022,451,00021,607,00021,943,00020,675,00021,162,000
Net income
20m
-23.48%
00000055,99102,557,22023,448,25601,769,000-39,149,0004,403,000543,0003,242,0004,549,0007,758,00026,636,00020,383,000
CFO
16m
+51.29%
0000001,242,80106,898,6667,020,29507,764,00011,469,00019,930,00011,284,0008,860,00011,691,00013,814,00010,575,00015,999,000
Earnings
Mar 12, 2025

Profile

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
IPO date
Feb 25, 2004
Employees
5
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
21,162
2.36%
20,675
-5.78%
21,943
1.56%
Cost of revenue
9,902
9,625
3,772
Unusual Expense (Income)
NOPBT
11,260
11,050
18,171
NOPBT Margin
53.21%
53.45%
82.81%
Operating Taxes
(7,702)
(15,157)
3,301
Tax Rate
18.17%
NOPAT
18,962
26,207
14,870
Net income
20,383
-23.48%
26,636
243.34%
7,758
70.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
(5,559)
(1,988)
(1,717)
BB yield
3.95%
0.48%
3.62%
Debt
Debt current
94
101
56
Long-term debt
612
755
976
Deferred revenue
Other long-term liabilities
Net debt
(39,119)
(46,921)
(39,370)
Cash flow
Cash from operating activities
15,999
10,575
13,814
CAPEX
(21)
(81)
Cash from investing activities
(144)
(81)
Cash from financing activities
(5,244)
(1,914)
(2,470)
FCF
15,808
26,170
17,483
Balance
Cash
39,825
28,836
20,548
Long term investments
18,941
19,854
Excess cash
38,767
46,743
39,305
Stockholders' equity
74,765
58,722
33,805
Invested Capital
42,106
12,861
(625)
ROIC
68.99%
428.37%
817.26%
ROCE
13.92%
18.54%
54.76%
EV
Common stock shares outstanding
25,422
107,486
26,830
Price
5.54
44.27%
3.84
116.95%
1.77
90.32%
Market cap
140,839
-65.88%
412,746
769.14%
47,489
86.60%
EV
101,720
365,825
8,119
EBITDA
12,487
12,039
18,872
EV/EBITDA
8.15
30.39
0.43
Interest
464
92
Interest/NOPBT
4.20%
0.51%